SCOTUS Backs Teva, Says Appeals Court Can't 'Set Aside' District Ruling

The Supreme Court handed Teva Pharmaceuticals a major win this week by ordering a federal appeals court to revisit its decision to shoot down a subset of Teva's patents for a complex multiple sclerosis drug, demanding the U.S. Court of Appeals for the Federal Circuit consider information generated by the district court unless it is found to be in "clear error." The high court's ruling may make it harder for brand and generic companies to get appeals courts to review...